Encouraging Data Presented by ALKS - Analyst Blog
July 01 2011 - 10:30AM
Zacks
Recently, Alkermes
Inc. (ALKS) presented encouraging top line data from an
early stage study of its schizophrenia candidate ALKS 9070
(n=32). ALKS 9070 is a once-monthly injectable extended
release version of Bristol-Myer Squibb’s (BMY)
schizophrenia drug Abilify (aripiprazole). Alkermes intends
to present complete data from the study at an upcoming medical
conference.
The double-blind, randomized,
placebo-controlled 20-week study evaluated the safety, tolerability
and pharmacokinetics of ALKS 9070 (once-monthly) at 3 doses in
patients suffering from chronic, stable schizophrenia.
Data from the study revealed that
the candidate was generally well tolerated at all doses and
achieved therapeutically relevant plasma concentrations of Abilify.
The pharmacokinetic profile backed the once-monthly dosing of ALKS
9070. Encouraged by the positive results, the company intends to
commence a pivotal development program for the candidate by the end
of the present calendar year.
Even though the positive results
for ALKS 9070 is a boost to Alkermes’ pipeline we believe that
investor focus will remain on the fate of diabetes drug, Bydureon,
in the US and its launch in the European Union. Alkermes has
co-developed Bydureon with Amylin Pharmaceuticals
(AMLN), Eli Lilly and Company (LLY).
Another event which is expected to
be in focus is the impending purchase of Elan
Corporation’s (ELN) drug delivery unit, Elan Drug
Technologies, by Alkermes. The merger is expected to close in the
third quarter of calendar 2011. The deal is expected to boost
Alkermes’ cash earnings immediately following its closure. The
product portfolio at Alkermes will be strengthened following the
merger. The merged entity is expected to possess a diversified
product portfolio (with 25 marketed products) and a robust
pipeline.
Our
Recommendation
Currently we have a ‘Neutral’
long-term recommendation for Alkermes. The company carries a Zacks
#3 Rank (‘Hold’ rating) in the short run.
ALKERMES INC (ALKS): Free Stock Analysis Report
AMYLIN PHARMA (AMLN): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
ELAN CP PLC ADR (ELN): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
Zacks Investment Research
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024